Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the
Company will present at the BMO Capital Markets Focus on Healthcare
Conference in New York, NY on Wednesday, August 5 at 3:30 p.m. ET.
Interested parties can access a live audio web cast of the presentation
at http://www.salix.com.
A replay of the presentation will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina,
develops and markets prescription pharmaceutical products for the
treatment of gastrointestinal diseases. Salix’s strategy is to
in-license late-stage or marketed proprietary therapeutic drugs,
complete any required development and regulatory submission of these
products, and market them through the Company’s gastroenterology
specialty sales and marketing team.
Salix markets XIFAXAN® (rifaximin) tablets 200 mg, OSMOPREP®
(sodium phosphate monobasic monohydrate, USP and sodium phosphate
dibasic anhydrous, USP) Tablets, MOVIPREP® (PEG 3350, Sodium
Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and
Ascorbic Acid for Oral Solution), VISICOL® (sodium phosphate
monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Tablets, APRISO™ (mesalamine) extended-release capsules 0.375 g., PEPCID®
(famotidine) for Oral Suspension, Oral Suspension DIURIL® (Chlorothiazide),
AZASAN® Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC®
2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg
Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream
(Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository
(Hydrocortisone Acetate Rectal Suppositories) 30 mg. METOZOLV™ ODT
(metoclopramide), budesonide foam, crofelemer and rifaximin for
additional indications are under development.
For full prescribing information on Salix products, please visit www.salix.com
or contact the Company at 919 862-1000.
Salix trades on the NASDAQ Global Select Market under the ticker symbol
“SLXP.”
For more information please visit our web site at www.salix.com
. Information on our web site is not incorporated in our SEC filings.
Salix Pharmaceuticals, Ltd.
Adam C. Derbyshire, Executive Vice
President and
Chief Financial Officer or
G. Michael Freeman,
Associate Vice President, Investor Relations
and Corporate
Communications, 919-862-1000
